Full Press Release Details
LEXINGTON, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the Canaccord Genuity 35th Annual Growth Conference on August 12, 2015 at the InterContinental in Boston, Massachusetts.
Event: Canaccord Genuity 35th Annual Growth Conference
Date: Wednesday, August 12, 2015
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra has initiated clinical testing of NS2 for the treatment of Sj gren-Larsson Syndrome and noninfectious anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com